Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Goserelin may be equivalent to chemotherapy for hormone-sensitive early breast cancer

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 265 No 7118 p541
October 14, 2000 Clinical

Goserelin may be equivalent to chemotherapy for hormone-sensitive early breast cancer

Goserelin (Zoladex) is as effective as standard chemotherapy for hormone-sensitive early breast cancer, according to new research.
Results from the ZEBRA (Zoladex in early breast cancer research association trial) study were presented at a European breast cancer care conference in Brussels on September 28. The study involved 1,640 pre- and perimenopausal women with early breast cancer who received either goserelin 3.6mg every 28 days for two years or six 28-day cycles of standard chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil).
In patients who were hormone-sensitive (73 per cent of the study population), goserelin was shown to be equivalent to chemotherapy in terms of disease-free survival. In patients who were not hormone-sensitive, chemotherapy gave better results. Goserelin was associated with fewer adverse effects than chemotherapy.
Professor Mike Baum (emeritus professor of surgery, University College London, and chairman, Cancer Research Campaign breast cancer trials group) told The Journal on October 10 that the ZEBRA results were “impressive”. The study showed that in oestrogen receptor-positive patients, chemotherapy or goserelin gave equivalent outcomes. He said that women should be aware that there might be alternatives to chemotherapy if they were hormone-receptor positive. “The gold standard for treatment was chemotherapy and tamoxifen but we have now got sufficient evidence to suggest that ovarian suppression and tamoxifen is equivalent,” he concluded.

Citation: The Pharmaceutical Journal URI: 20003233

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.